Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Netherlands limits use of AstraZeneca vaccine to people over 60

04/08/2021 | 02:32pm EDT

AMSTERDAM, April 8 (Reuters) - The Dutch government will limit use of the AstraZeneca COVID-19 vaccine to people above age 60 following rare cases of blood clots, Health Minister Hugo de Jonge said on Thursday.

The decision came a day after Europe’s medicines regulator said it found rare cases of blood clots among some adult recipients of the shot, although the vaccine’s advantages still outweighed its risks.

"People over the age of 60, born in 1960 or earlier, can safely continue to receive an injection of AstraZeneca. People under the age of 60 will receive a different vaccine," the government said in statement.

The Netherlands, which has ordered 12 million AstraZeneca doses, is among several countries to restrict the vaccine's use in recent days following concerns about side effects.

But de Jonge stressed the greater risks for older adults from COVID-19.

"The risk of health damage as a result of COVID-19 in people over 60 is many times greater than the risk of the very rare reported side effect of severe thrombosis with a low platelet count," he said.

The vaccine, which AstraZeneca developed with Oxford University and considered a frontrunner in the global vaccine, has been plagued by safety concerns and supply problems. (Reporting by Anthony Deutsch Editing by Chris Reese and Leslie Adler)


© Reuters 2021
All news about ASTRAZENECA PLC
07:29aASTRAZENECA  : Secures US Nod For $39 Billion Alexion Deal
MT
06:47aEU to Focus on mRNA-based COVID-19 Jabs, Likely to Ditch AstraZeneca, Johnson..
MT
05:18aASTRAZENECA  : CEO Says Borders Need To Open To Keep Sharing Vaccines Through CO..
MT
05:03aASTRAZENECA  : Indian vaccine maker Serum Institute appeals to Biden to lift emb..
RE
04:06aASTRAZENECA  : vaccine available to walk-ins
AQ
02:29aASTRAZENECA  : India extends record rise in COVID-19 cases, election rallies con..
RE
04/15MARKET CHATTER : Elliott Management Secures 'Significant' Shareholding in GlaxoS..
MT
04/15ANALYSIS : India shifts from mass vaccine exporter to importer, worrying the wor..
RE
04/15MODERNA  : Fauci says he believes J&J vaccine will 'get back on track soon'
RE
04/15ASTRAZENECA  : Quebec officials satisfied with AstraZeneca rollout despite empty..
AQ
More news
Financials (USD)
Sales 2021 30 821 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 685 M - -
P/E ratio 2021 26,1x
Yield 2021 2,80%
Capitalization 134 B 134 B -
EV / Sales 2021 4,72x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 101,99 $
Spread / Highest target 62,7%
Spread / Average Target 27,1%
Spread / Lowest Target -7,66%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC1.04%133 910
JOHNSON & JOHNSON1.91%422 260
ROCHE HOLDING AG-0.02%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-4.51%197 072
MERCK & CO., INC.-6.28%194 049